Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Caspase Inhibitor Set I Nowadays colorimetric assay has been
2021-01-25

Nowadays, colorimetric assay has been applied in detecting DNA MTase activity. Li et al. used DNA modified gold nanoparticles (AuNPs) coupled with enzyme-linkage reactions to detect the activity of methylases [20]. In a previous study, our group presented a label-free colorimetric method, using unmo
-
br Materials and Methods br Results br Discussion
2021-01-23

Materials and Methods Results Discussion Even though T cell checkpoint inhibitors alone have achieved impressive clinical benefit in some cancers, their application as single agents has had limited efficacy (Hamid et al., 2013; Wolchok et al., 2013). The resistance to immunotherapy is in pa
-
Identification of the drug to be used as first step
2021-01-23

Identification of the drug to be used as first-step antihypertensive treatment has always been, and remains, a matter of debate. The decision wihich drug (or drug combination) to choose as first-line therapy depend on many variables such as coexisting metabolic disorders, obesity, presence of subcli
-
Our previous high throughput screening HTS campaign using au
2021-01-23

Our previous high-throughput screening (HTS) campaign using automated, robust, and sensitive fluorescence based Navitoclax assay [10], [11] led to the identification of several EPAC specific inhibitors (ESIs), and was subsequently followed by extensive hit-to-lead optimizations [20], [21], [22], [2
-
br Results br Discussion In this paper
2021-01-23

Results Discussion In this paper we present insights into the observed specificities of inhibitors targeting the ubiquitin-activating and related E1 n oxide via crystal structures of the specific NEDD8-E1 inhibitor MLN4924, the dual NEDD8/Ub E1 inhibitor ABPA3, and the selective Ub-E1 inhibit
-
The majority of serpins inhibit serine proteases but serpins
2021-01-23

The majority of serpins inhibit serine proteases, but serpins that inhibit caspases or papain-like cysteine proteases have also been identified [4], [5]. Inhibitory serpins are ‘suicide’ or ‘single use’ inhibitors that use a unique conformational change to inhibit proteases. This conformational tran
-
Numerous studies have investigated the contribution of N
2021-01-23

Numerous studies have investigated the contribution of N-cadherin to metastasis and tumorigenesis. The overexpression of N-cadherin has been shown to enhance tumor invasion and motility in multiple cancer models [25,40,48]. Transforming growth factor beta 1 (TGFβ1) is a strong EMT inducer. In fact,
-
Gene expression profiling with corresponding clinical data s
2021-01-23

Gene VSV-G Peptide profiling with corresponding clinical data supported the notion that increased expression of S1PR1 in DLBCL was associated with poor outcome [159], [160], [161]. These studies also identified increased expression of the GPCRs GPR183, CCR7, ADRB2 and CNR2 as risk factors for poor
-
E ubiquitin ligases are key players in the
2021-01-23

E3 ubiquitin ligases are key players in the ubiquitin-proteasome pathway because they catalyse ubiquitination of substrate proteins.39, 40, 41 As important regulators of cellular ubiquitination, E3 ligases are emerging as attractive drug targets, particularly in cancer.42, 43, 44 However, E3 ligases
-
Verteporfin sale AMPHs facilitate dopamine release which fur
2021-01-23

AMPHs facilitate dopamine release, which further triggers dopamine depletion [72]. Indeed, we observed that repeated treatment of MPA significantly inhibited TH-, DAT-, and VMAT-2 levels. Since DAT and VMAT-2 are important for dopaminergic terminal markers [10], their decreases suggest that MPA-indu
-
The CysLT receptor antagonist BayCysLT RA significantly supp
2021-01-22

The CysLT2 receptor antagonist BayCysLT2RA significantly suppressed multiple antigen challenge-induced infiltration of eosinophils and mononuclear vegf tyrosine kinase inhibitor into the lung, indicating that CysLT2 receptor activation is involved in leukocyte migration. In contrast to the present
-
br Most reported binding data are obtained
2021-01-22

Most reported binding data are obtained by performing heterologous competition binding experiments and expressing the results as relative binding affinity (RBA). The constructed binding curves should theoretically be sigmoidal in shape with a Hill slope value of one, for a single ligand binding to
-
Three kinase inhibitors dasatinib type I imatinib type II an
2021-01-22

Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007, Hantschel et al., 2008). These tyrosine kinase inhibitors
-
Methylation of histone tails is
2021-01-21

Methylation of histone tails is important in regulating Cyanine 5-dCTP sale structure and transcription. Methylation occurs at arginine and at mono-, di- or tri-methylated lysine residues. The reversibility of histone methylation was recently revealed by the identification of two histone demethylas
-
Indeed a significant difference was observed for the binding
2021-01-21

Indeed, a significant difference was observed for the binding of glycated α-synuclein. Thus, g-α-synuclein bound to other part of GAPDH in 4 of 10 simulations (Fig. 2F, brown, yellow and dark-green chains, and Fig. 2G, brown chain). This additional binding site is located on the interface between O
16219 records 744/1082 page Previous Next First page 上5页 741742743744745 下5页 Last page